- JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report1
- Lecanemab for early Alzheimer’s disease: final evidence report1
- Mavacamten for hypertrophic cardiomyopathy: effectiveness and value : final evidence report and meeting summary1
- Medications for obesity management: effectiveness and value : final evidence report1
- Mepolizumab (Nucala??, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report1
- Modulator treatments for cystic fibrosis: effectiveness and value1
- Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report1
- Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects: revised evidence report1
- Obeticholic acid for the treatment of nonalcoholic steatohepatitis: comparative clinical effectiveness and value : evidence report1
- Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks : evidence report1
- Oral immunotherapy and Viaskin Peanut for peanut allergy: effectiveness and value : final evidence report1
- PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report1
- Palliative care in the outpatient setting: a comparative effectiveness report : final report1
- Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report1
- Special assessment of outpatient treatments for COVID-19: final evidence report and meeting summary1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- Strengthening the accelerated approval pathway: an analysis of potential policy reforms and their impact on uncertainty, access, innovation, and costs1
- Supervised injection facilities and other supervised consumption sites: effectiveness and value : final report1
- Targeted immune modulators for ulcerative colitis: effectiveness and value : final evidence report and meeting summary1
- Tezepelumab for severe asthma: final report2